Loading provider…
Loading provider…
Hematology & Oncology Physician in Tampa, FL
NPI: 1134464910Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. Dae Won's Phone Numberphone_androidMobile
Get M.D. Dae Won's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2017 - 2027

American Board of Internal Medicine
Medical Oncology
Icahn School of Medicine at Mount Sinai/Morningside/West
Residency • Internal Medicine
2010 - 2013
Other
Medical School
Until 1999
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 128 | 324 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 100 | 100 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 18 | 24 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
Authors: Young Cha, Jessica Warsch, Mohammad Jahanzeb, Gilberto Lopes, Mohamed El Dinali, Sean Warsch, Raja Mudad, Chukwuemeka Ikpeazu, Diana Saravia, Fernando Vargas Madueno
Publication Date: 2017-12-21
Authors: Vikram Krishnamurthy, Steven Bines, Howard Kaufman
Journal: Hum Vaccin
Publication Date: 2010-10-01
Authors: Jason Fleming, Sarah Hoffe, Fernando De Zarraga, Antonio Ucar, Horacio Asbun, Pamela Hodul, Russell Palm, Jessica Frakes, Adeel Kaiser, Roberto Herrera, Mokenge Malafa, Jason Denbo, Santiago Aparo, Jason Fleming, Michael Chuong, Ramon Jimenez
Journal: Cancer Control
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: DRUG: Sorafenib, DRUG: Trametinib
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: DRUG: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA], DRUG: TAS 102
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Gemcitabine, DRUG: Nab-paclitaxel, DRUG: Olaratumab